Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)

• Company Description    Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $0.80 Daily Weekly Monthly 20 Day Moving Average: 552,899 shares Shares Outstanding: 21.06 (millions) Market Capitalization: $16.85 (millions) Beta: 0.16 52 Week High: $2.31 52 Week Low: $0.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.11% -1.94% 12 Week 17.56% 11.90% Year To Date -53.76% -59.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1951 NW 7TH AVENUE SUITE 520 - MIAMI,FL 33136 USA ph: 305-909-0840 fax: - investorrelations@longeveron.com https://longeveron.com

• General Corporate Information    Officers Mohamed Wa'el Ahmed Hashad - Chief Executive Officer Lisa A. Locklear - Executive Vice President and Chief Financial Offic Joshua M. Hare - Director Rock Soffer - Director Richard Kender - Director Peer Information Longeveron Inc. (CORR.) Longeveron Inc. (RSPI) Longeveron Inc. (CGXP) Longeveron Inc. (BGEN) Longeveron Inc. (GTBP) Longeveron Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54303L203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/27/26 Share - Related Items Shares Outstanding: 21.06 Most Recent Split Date: 3.00 (0.10:1) Beta: 0.16 Market Capitalization: $16.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.96 Price/Cash Flow: - Price / Sales: 11.72 EPS Growth vs. Year Ago Period: -14.71% vs. Previous Quarter: -18.18% Sales Growth vs. Year Ago Period: -82.28% vs. Previous Quarter: -56.65% ROE 09/30/25 - -123.85 06/30/25 - -95.91 03/31/25 - -85.07 ROA 09/30/25 - -101.38 06/30/25 - -79.69 03/31/25 - -70.74 Current Ratio 09/30/25 - - 06/30/25 - 3.43 03/31/25 - 5.61 Quick Ratio 09/30/25 - - 06/30/25 - 3.43 03/31/25 - 5.61 Operating Margin 09/30/25 - -1,485.25 06/30/25 - -894.40 03/31/25 - -760.72 Net Margin 09/30/25 - -1,485.25 06/30/25 - -894.40 03/31/25 - -760.72 Pre-Tax Margin 09/30/25 - - 06/30/25 - -894.40 03/31/25 - -760.72 Book Value 09/30/25 - - 06/30/25 - 0.83 03/31/25 - 1.15 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©